Content Validity Assessment of a Newly-Developed Patient-Reported Outcome Measure for Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), and Sjogren's Syndrome Dry Eye Disease (SS-DED)

Sloesen B¹, Young A², Hodson N², Smith V², Walsh O¹, Naujoks C¹, Sharma G³, O'Brien P⁴, Arbuckle R²

¹Novartis Pharma AG, Basel, Switzerland; ²Adelphi Values Ltd, Bollington, UK; ³Novartis Healthcare Pvt. Ltd., Hyderabad, India; **Novartis Ireland Limited, Dublin, Ireland**

Introduction

- Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), and Sjögren's Syndrome Dry Eye Disease (SS-DED) are conditions associated with symptoms of ocular discomfort caused by inadequate lubrication of the eye. 1-3
- Key symptoms across the three conditions, such as ocular dryness, grittiness, burning sensation, and pain can cause patients to experience difficulties performing activities of daily living and can significantly impact the physical, emotional, and social domains of patients' Health-Related Quality of Life (HRQoL).4-6
- A targeted literature search showed lack of suitable PRO measures for use in DED, MGD, and SS-DED for capturing the patient experience of symptoms and impacts on different aspects of daily life. Additional qualitative research was undertaken to further understand the patient experience and inform the content of a new measure, the Dry Eye Disease Questionnaire (DED-Q).

Objective

• The aim of this research was to evaluate the content validity of the Dry Eye Disease Questionnaire (DED-Q), a newly-developed patient-reported outcome measure for use in DED, MGD, and SS-DED.

Methods

- A first version of the DED-Q was developed based on qualitative literature review in DED, MGD, and SS-DED and previous qualitative research in patients with Chronic Ocular Surface Pain (COSP), some of whom had DED, and aimed to assess patients' experience of symptoms, ability to perform visual activities, and impact on HRQoL.
- Cognitive debriefing (CD) of the DED-Q was conducted with a sample of 60 US adults who reported experiencing ocular symptoms due to their condition and had a physicianconfirmed primary diagnosis of DED (n=20), MGD (n=20), or SS-DED (n=20).
- Interviews were conducted over two rounds and employed a 'think aloud' approach to evaluate patients' understanding of the instructions, items, response options, and recall periods, and to obtain feedback on perceived relevance of concepts assessed across various modules.8
- Interviews were also conducted with eight health care professionals to assess clinical relevance of the concepts included.
- Input was sought at key timepoints during the research from three clinical experts (n=1 US; n=1 France; n=1 Greece) to ensure that a clinical perspective of study findings was obtained.
- Verbatim interview transcripts were analyzed in ATLAS.ti v8 using dichotomous codes to assess understanding and relevance of each item, instruction, response option(s) and recall period.

Results

 Participating patients had a mean age of 50 years (range 21-80 years), were mostly female (64%), and were representative of a range of racial, ethnic, and socioeconomic backgrounds. **Table 1.** details the patient demographic and clinical information.

Table 1. Patient demographic and clinical information

	DED (n=20)	MGD (n=20)	SS-DED (n=20)	Total sample (N=61)
Age (average, range)	47 (21-74)	49 (20-76)	54.5 (29-80)	50.2 (21-80)
Gender (n, %)				
Female	14 (70%)	15 (75%)	9 (45%)	38 (63.3%)
Male	6 (30%)	5 (25%)	11 (55%)	22 (36.7%)
Race (n, %)				
White/Caucasian	7 (35%)	8 (40%) 12 (60%)		27 (45%)
Black/African American	9 (45%)	7 (35%)	3 (15%)	19 (31.7%)
Asian	0 (0%)	2 (10%)	2 (10%)	4 (6.7%)
Hispanic/Latino	3 (15%)	2 (10%)	2 (10%)	7 (11.7%)
Mexican	1 (5%)	1 (5%)	0 (0%)	2 (3.3%)
Other (not specified)	0 (0%)	0 (0%)	1 (5%)	1 (1.7%)
Ethnicity (n, %)				
Non-Hispanic or Latino	14 (70%)	13 (65%)	13 (65%)	40 (66.7%)
Hispanic or Latino	6 (30%)	7 (35%)	7 (35%)	20 (33.3%)
Work status (n, %)				
Retired	1 (5%)	2 (10%) 6 (30%)		9 (15%)
Working full time	12 (60%)	12 (60%)	13 (65%)	37 (61.7%)
Working part time	3 (15%)	1 (5%)	1 (5%)	5 (8.3%)
Looking for work	0 (0%)	2 (10%)	0 (0%)	2 (3.3%)
Homemaker	1 (5%)	1 (5%)	0 (0%)	2 (3.3%)
Student	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Volunteer	1 (5%)	0 (0%)	0 (0%)	1 (1.7%)
Not working due to eye condition	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Not working due to another health condition	2 (10%)	2 (10%)	0 (0%)	4 (6.7%)
Severity of eye condition (n, %)				
Mild	3 (15%)	6 (30%)	5 (25%)	14 (23.3%)
Moderate	11 (55%)	10 (50%)	10 (50%)	31 (51.6%)
Severe	6 (30%)	4 (20%)	5 (25%)	15 (25%)

Cognitive debriefing findings from Round 1

- Most HCPs indicated the selected symptom and impact concepts are relevant to assess in the populations of interest.
- Except for items assessing eye dryness, all items and response options were very well understood by almost all patients, and concepts were largely considered relevant to most patients' experiences.
- Based on the findings and input of three clinical experts, modifications were made to enable better interpretation and to improve overall concept relevance across the patient groups. **(Table 2.)**


Table 2. Modifications based on the round 1 CD findings in DED, MGD, SS-DED patients

Module	Item/Instruction prior to CD interview	Understanding (n/asked)	Concept relevant (n/asked)	Modifications	Revised item/Instruction post CD (with highlighted changes)
Eye dryness severity module	"Please rate the severity of your eye dryness right now (0=No eye dryness, 10=Worst possible eye dryness)"	8/30	12/12	Item wording revised to focus on eye dryness rather than symptoms	"Please rate the severity of your eyes feeling dry right now (0=no dry feeling in my eyes, 10=worst possible dry eye feeling in my eyes)."
Eye dryness frequency module	"How much of the time have you had eye dryness in the past 24 hours?"	8/29	12/12	related to dry eye disease	"How much of the time have your <u>eyes felt dry</u> in the past 24 hours?"
Symptom module	"Please answer the following questions thinking about each symptom at the time it was at its worst over the past 24 hours."	12/19	Not applicable	Slight wording modifications to instructions to simplify the recall period	"Please answer the following questions thinking about each symptom when it was at its worst_over the past 24 hours."
Symptom module	"Eye dryness: Please rate the severity of your eye dryness at its worst in the past 24 hours. (0=No eye dryness, 10=Worst possible eye dryness)."	12/29	12/12	Item wording and response scale anchors revised to align with changes to the eye dryness module	"Eye dryness: Please rate the severity of your eyes feeling dry at its worst in the past 24 hours (0=No dry eye feeling, 10=worst possible dry eye feeling)."
Symptom module	"Eye redness: please rate the severity of your eye redness at its worst in the past 24 hours."	28/30	24/28	Item modified to differentiate redness of the eye itself from eyelid redness	"Eyeball redness: please rate the severity of your eyeball redness at its worst in the past 24 hours."
Environmental triggers module	"Sensitivity to light: please rate how sensitive your eyes have been to light at its worst in the past 24 hours." Sensitivity to wind: (same as above)	21/22	21/21	Environmental triggers could induce a confounding effect in interpretation of clinical trial results. Module removed	Not applicable
Visual tasking module	"The following questions ask about how much of the time your dry eye disease symptoms and problems affected with your ability to do visual activities in the past 7 days."	11/15	Not applicable	Additional instructions were added for clarity	"The followingin the past 7 days. Please do not think about any other vision problems you have (such as vision problems that are corrected by wearing glasses, reading glasses, or contact lenses) when selecting an answer."

Cognitive debriefing findings from Round 2

- The items were again generally very well understood by almost all patients and most concepts were relevant to greater than 75% of the patients. [Figure 1. presents sample quotes from both the interview rounds].
- Despite modifications to the items assessing eye dryness, some patients still tended to refer to their overall dry eye disease symptoms rather than the sensation of eye dryness only.
- As for now, all items assessing eye dryness have been retained without further modification for testing in a larger sample during initial psychometric evaluation analyses of the DED-Q.

Figure 1. Example quotes illustrating patient understanding of DED-Q



Conclusions

- No key differences in understanding or concept relevance were identified between rounds of interviews for any items of the DED-Q.
- The CD findings support the content validity of the DED-Q for use in clinical studies to assess the symptoms and functional impacts of DED, MGD, and SS-DED.
- Additional psychometric analysis studies are needed to further refine these measures and confirm their suitability as clinical trial endpoints to support product labeling claims.

References

1. Stapleton F, et al. Ocul Surf. 2017;15(3):334-65. 2. Farrand KF, et al. Am J Ophthalmol. 2017;182:90-98. 3. Baudouin C, et al. Br J Ophthalmol. 2016;100(3):300-6. 4. Labetoulle M, et al. Br J Ophthalmol. 2019;103(10):1475-80. 5. Champey J, et al. Arthritis Rheum. 2006;55(3):451-7. 6. Friedman NJ. Curr Opin Ophthalmol. 2010;21(4):310-6.

Poster presented at the Professional Society for Health Economics and Outcomes Research (ISPOR) Congress 6-9 November 2022.

To download a copy of this poster, visit the web at: Copies of this poster obtained through Quick Response (QR) code are for personal use only and may not be reproduced without written permission of the authors.